Shares of Concert Pharmaceuticals Inc (NASDAQ:CNCE) have been given a consensus rating of “Hold” by the ten ratings firms that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $20.00.
CNCE has been the topic of several research reports. Zacks Investment Research raised shares of Concert Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Wednesday, May 1st. TheStreet cut shares of Concert Pharmaceuticals from a “c-” rating to a “d” rating in a research report on Friday, March 1st. HC Wainwright reaffirmed a “buy” rating on shares of Concert Pharmaceuticals in a research report on Friday, March 1st. Mizuho reaffirmed a “buy” rating on shares of Concert Pharmaceuticals in a research report on Friday, May 3rd. Finally, BidaskClub cut shares of Concert Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, March 27th.
Shares of NASDAQ CNCE traded down $0.10 during midday trading on Friday, reaching $10.94. 4,158 shares of the stock were exchanged, compared to its average volume of 235,094. The stock has a market cap of $258.19 million, a price-to-earnings ratio of -4.60 and a beta of 0.88. Concert Pharmaceuticals has a 12 month low of $9.21 and a 12 month high of $20.62. The company has a quick ratio of 20.44, a current ratio of 20.44 and a debt-to-equity ratio of 0.11.
Concert Pharmaceuticals (NASDAQ:CNCE) last posted its quarterly earnings data on Thursday, May 2nd. The biotechnology company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.31). The company had revenue of $1.01 million during the quarter, compared to the consensus estimate of $16.08 million. Concert Pharmaceuticals had a negative net margin of 7,118.04% and a negative return on equity of 41.72%. On average, research analysts anticipate that Concert Pharmaceuticals will post -3.86 EPS for the current fiscal year.
Hedge funds have recently modified their holdings of the business. Great West Life Assurance Co. Can acquired a new stake in Concert Pharmaceuticals in the 4th quarter valued at $48,000. BNP Paribas Arbitrage SA increased its stake in Concert Pharmaceuticals by 63,200.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 4,431 shares of the biotechnology company’s stock valued at $53,000 after buying an additional 4,424 shares during the last quarter. Citigroup Inc. increased its stake in Concert Pharmaceuticals by 32.5% in the 1st quarter. Citigroup Inc. now owns 7,091 shares of the biotechnology company’s stock valued at $85,000 after buying an additional 1,739 shares during the last quarter. Metropolitan Life Insurance Co. NY increased its stake in Concert Pharmaceuticals by 452.1% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 7,553 shares of the biotechnology company’s stock valued at $95,000 after buying an additional 6,185 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale increased its stake in Concert Pharmaceuticals by 21.6% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 9,000 shares of the biotechnology company’s stock valued at $143,000 after buying an additional 1,600 shares during the last quarter. Hedge funds and other institutional investors own 67.38% of the company’s stock.
About Concert Pharmaceuticals
Concert Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, a once-nightly oxybate product; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata.
Featured Story: What impact do institutional investors have on markets?
Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.